Abstract
Cardiovascular disease, including atherothrombosis, is the most frequent cause of mortality in the Western World. In the last years, major advances have been made in the pathogenesis of this disease. Currently, the drugs most widely used are the inhibitors of the HMG-CoA reductase (statins) and the antihypertensive drugs, mainly angiotensin II blockers. The first group has been shown to be effective on cardiovascular disease due to atherothrombosis, and the second group on hypertensive disease. Nevertheless, recent data suggest that these two situations can improve with the concomitant use of both drugs.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Angiotensin II / antagonists & inhibitors*
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Animals
-
Anticholesteremic Agents / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Arteriosclerosis / drug therapy*
-
Arteriosclerosis / physiopathology
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular Diseases / prevention & control
-
Cholesterol / blood
-
Cyclooxygenase Inhibitors / therapeutic use
-
Endothelium, Vascular / physiopathology
-
Haplorhini
-
Humans
-
Hypertension / drug therapy
-
Hypolipidemic Agents / therapeutic use*
-
Lipid Metabolism
-
Randomized Controlled Trials as Topic
-
Renin-Angiotensin System / drug effects
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Anticholesteremic Agents
-
Antihypertensive Agents
-
Cyclooxygenase Inhibitors
-
Hypolipidemic Agents
-
Angiotensin II
-
Cholesterol